Drugs /

zimberelimab

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, zimberelimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.

Clinical Trials

View Clinical Trials for zimberelimab

Zimberelimab has been investigated in 11 clinical trials, of which 11 are open and 0 are closed. Of the trials investigating zimberelimab, 1 is early phase 1 (1 open), 6 are phase 1 (6 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open).

EGFR A763_Y764insFQEA, EGFR Codon 719 Missense, and EGFR Exon 19 Deletion are the most frequent biomarker inclusion criteria for zimberelimab clinical trials.

Malignant solid tumor, non-small cell lung carcinoma, and prostate carcinoma are the most common diseases being investigated in zimberelimab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Zimberelimab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating zimberelimab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
wbp-3055, gls-010, ab122, ab 122, ab-122, gls 010, gls010, anti-pd-1 monoclonal antibody gls-010
Drug Categories [2]:
Anti-PD-1 antibodies
Drug Target(s) [2]:
PDCD1
NCIT ID [1]:
C159549

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.